Kirsten Lew, NP
Critical Care Medicine · League City, TXNPI 1295329662
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 128 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 16.9% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,014, 2.4 times the $417 reported in 2021.
Across 128 payments — averaging $18.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$407
- Eisai Inc.$303
- Lilly USA, LLC$170
- Supernus Pharmaceuticals, Inc.$161
- SK Life Science, Inc.$130
- Amneal Pharmaceuticals LLC$127
- plus $1K from 24 others
What the payments were for
- Food & beverage$2,402100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 34 | $407 |
| Eisai Inc. | 14 | $303 |
| Lilly USA, LLC | 9 | $170 |
| Supernus Pharmaceuticals, Inc. | 8 | $161 |
| SK Life Science, Inc. | 6 | $130 |
| Amneal Pharmaceuticals LLC | 6 | $127 |
| Biogen | 5 | $111 |
| Avion Pharmaceuticals | 6 | $110 |
| Pfizer | 4 | $98 |
| Lundbeck LLC | 3 | $79 |
| Jazz Pharmaceuticals Inc. | 3 | $77 |
| Amgen | 3 | $74 |
| AstraZeneca | 2 | $52 |
| UCB, Inc. | 2 | $51 |
| Otsuka America Pharmaceutical, Inc. | 2 | $48 |
| Acadia Pharmaceuticals Inc | 2 | $47 |
| Adamas Pharmaceuticals, Inc. | 2 | $46 |
| CSL Behring | 2 | $33 |
| Azurity Pharmaceuticals, Inc. | 2 | $31 |
| Axsome Therapeutics, Inc. | 1 | $29 |
| Saluda Medical Americas, Inc. | 1 | $27 |
| Medtronic | 1 | $26 |
| Aucta Pharmaceuticals, Inc. | 3 | $25 |
| Impel Pharmaceuticals LLC | 1 | $25 |
| Argenx US, Inc. | 1 | $23 |
| Neurocrine Biosciences, Inc. | 1 | $22 |
| Teva Pharmaceuticals USA, Inc. | 1 | $20 |
| Upsher-smith Laboratories LLC | 1 | $18 |
| Avanir Pharmaceuticals, Inc. | 1 | $18 |
| Aquestive Therapeutics, Inc. | 1 | $17 |
How this compares
$2,402 in reported general payments places this provider in the 75th percentile of 507 critical care medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other critical care medicine in League City
- Steven DavidoffPlano$364K
- William BartekAustin$284K
- Edwin ParsleyHouston$283K
- Hector PayanEl Paso$245K
- Bindu AkkantiHouston$185K
- Faisal MasudHouston$155K
- Sergio Trevino CastilloHouston$133K
- Akinyinka AjelabiKingwood$109K
- Anthony OrtegonDallas$106K
- Gary WeinsteinDallas$103K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.